Nuvectis Pharma, Inc. NVCT Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Returns | |||||
| Return on equity | -188%-14.6pp | -173.4%-4.9pp | -168.5%— | —— | |
| Return on assets | -105.1%-4.6pp | -100.6%+11.9pp | -112.5%+28.6pp | -141%— | |
| Liquidity | |||||
| Current ratio | 2.4×+0.3× | 2.1×-0.7× | 2.7×-0.6× | 3.3×+0.9× | |
| Quick ratio | 2.4×+0.3× | 2.1×-0.7× | 2.7×-0.6× | 3.3×+0.9× | |
| Cash ratio | 2.4×+0.3× | 2.1×-0.7× | 2.7×-0.5× | 3.2×+0.9× | |
| Per Share | |||||
| Book value per share | $0.84+48.7% | $0.57-27.6% | $0.78-30.2% | $1.12+144% | |
| Valuation | |||||
| Market capitalization | $739.27M+335% | $104.53M-28.0% | $145.27M+32.3% | $109.82M— | |
| Price / book | 52×+43.9× | 10.8×-1.1× | 11.9×+4.2× | 7.7×— | |
| Earnings yield | -3.7%+8.2pp | -18.2%-2.9pp | -15.3%+2.1pp | -17.4%— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Nuvectis Pharma, Inc.'s ratios come from?
- Every ratio is computed from Nuvectis Pharma, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.